Showing 4131-4140 of 10903 results for "".
- "20 Tips in 20 Minutes" Offers Practical Pearls at Fall Clinicalhttps://practicaldermatology.com/news/20-tips-in-20-minutes-offers-practical-pearls-at-fall-clinical/2488740/Five dermatologists shared rapid-fire clinical, procedural, and practice-management advice, ranging from alopecia photography and nail examination to infantile hemangiomas, reimbursement, and patient communication at the 2026 Fall Clinical Dermatology Conference. The fast-moving "20 Tips i
- Dr. James Del Rosso Reviews Emerging Topical Therapieshttps://practicaldermatology.com/news/dr-james-del-rosso-reviews-emerging-topical-therapies/2488730/Advances in photoprotection, sebum-targeted acne treatment, and nonsteroidal topical therapies are expanding the range of topical options available to dermatologists, according to James Q. Del Rosso, DO, in one of his annual presentations at the 2026 Fall Clinical Dermatology Conference, titled "
- UCB Launches Wear It Out Campaign to Raise Awareness of HS, Psoriasis, and Psoriatic Arthritishttps://practicaldermatology.com/news/ucb-launches-wear-it-out-campaign-to-raise-awareness-of-hs-psoriasis-and-psoriatic-arthritis/2488727/UCB has launched Wear It Out, a patient-centered awareness initiative designed to address stigma and highlight the everyday challenges experienced by people living with hidradenitis suppurativa (HS), plaque psoriasis, and psoriatic arthritis (PsA). Announced October 13, the program was dev
- Expert Panel Proposes Practical Treatment Algorithm for Pediatric Molluscum Contagiosumhttps://practicaldermatology.com/news/expert-panel-proposes-practical-treatment-algorithm-for-pediatric-molluscum-contagiosum/2488716/A pediatric dermatology expert panel has proposed a practical treatment algorithm for molluscum contagiosum that emphasizes disease severity, family preferences, and shared decision-making. Presented in a 2026 Fall Clinical Dermatology Conference poster, the framework addresses a common, transmis
- Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/dupilumab-associated-with-lower-atopic-march-risk-in-pediatric-atopic-dermatitis/2488713/Children with atopic dermatitis (AD) who initiated dupilumab had a lower observed risk of developing additional atopic conditions than matched patients treated with systemic corticosteroids, according to a retrospective US claims study presented at the 2026 Fall Clinical Dermatology Conference.</
- Bleeding Events Infrequent Around Procedures in Remibrutinib CSU Trial Analysishttps://practicaldermatology.com/news/bleeding-events-infrequent-around-procedures-in-remibrutinib-csu-trial-analysis/2488707/A post hoc analysis of the phase 3 REMIX-1 and REMIX-2 trials found that bleeding events were uncommon among patients receiving remibrutinib who underwent surgical or invasive procedures. The findings were presented at the 2026 Fall Clinical Dermatology Conference.1 Remibrutinib
- Facial Volume Loss, Hair Changes Among GLP-1 Dermatologic Concerns: Analysishttps://practicaldermatology.com/news/facial-volume-loss-hair-changes-among-glp-1-dermatologic-concerns-analysis/2488695/A new narrative review published in Clinics in Dermatology took a closer look at the cutaneous effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), including facial volume loss, hair changes, skin laxity, and potential benefits in inflammatory skin diseases. Researcher
- Envudeucitinib Improves Itch by Week 2 in Phase 3 Plaque Psoriasis Trialshttps://practicaldermatology.com/news/envudeucitinib-improves-itch-by-week-2-in-phase-3-plaque-psoriasis-trials/2488683/Investigational oral tyrosine kinase 2 (TYK2) inhibitor envudeucitinib produced clinically meaningful itch improvement as early as week 2 in patients with moderate-to-severe plaque psoriasis, according to 24-week results from the phase 3 ONWARD1 and ONWARD2 trials. Jason E. Hawkes, MD, and
- Zasocitinib Outperforms Deucravacitinib in Phase 3 Head-to-Head Psoriasis Trialhttps://practicaldermatology.com/news/zasocitinib-outperforms-deucravacitinib-in-phase-3-head-to-head-psoriasis-trial/2488633/Investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) demonstrated superior skin clearance compared with deucravacitinib in adults with moderate-to-severe plaque psoriasis, according to phase 3 data presented at the European Academy of Dermatology & Venereology (EADV)
- Acrotech Brings Difamilast 1% Ointment for Atopic Dermatitis to UShttps://practicaldermatology.com/news/acrotech-brings-difamilast-1-ointment-for-atopic-dermatitis-to-us/2488630/Acrotech Biopharma Inc. announced the United States launch of ADQUEY (difamilast 1%) ointment, a nonsteroidal topical treatment for mild-to-moderate atopic dermatitis (AD) in adults and pediatric patients aged 2 years and older. Difamilast was originally developed by Otsuka Pharmaceutical